AngioDynamics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANGO research report →
Range $18 – $20
Price Chart
About the company
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets.
- CEO
- Eric Honroth
- IPO
- 2004
- Employees
- 632
- HQ
- Latham, NY, US
Get TickerSpark's AI analysis on ANGO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $454.61M
- P/E
- -14.54
- Fwd P/E
- 49.14
- PEG
- 1.72
- P/S
- 1.49
- P/B
- 2.94
- EV/EBITDA
- -46.59
- Div Yield
- 0.00%
- Gross Margin
- 55.65%
- Op Margin
- -11.24%
- Net Margin
- -10.12%
- ROE
- -19.25%
- ROIC
- -19.87%
Latest fiscal year · YoY change
- Revenue
- $320.17M+9.5%
- Gross Profit
- $174.89M+10.9%
- Op Income
- $-39,927,000
- Net Income
- $-36,742,000-8.1%
- EPS
- $-0.88-6.0%
- OCF Growth
- +130.5%
- FCF Growth
- +103.5%
- 52W High
- $16.29
- 52W Low
- $9.39
- 50D MA
- $13.11
- 200D MA
- $12.57
- Beta
- 0.28
- RSI (14)
- 33
- Avg Volume
- 646.78K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
AngioDynamics started fiscal 2027 with 6.9% revenue growth, stronger margins, and raised confidence that medtech will become the majority of sales this year.· October 8, 2026
- Revenue rose 6.9% to $80.9 million, led by medtech growth of 13.2%; medtech was 49% of total revenue versus 47% a year ago.
- Auryon extended its double-digit growth streak to 21 consecutive quarters, and NanoKnife posted 29% revenue growth with record prostate procedure volumes.
- Mechanical thrombectomy grew as AlphaVac accelerated 37.4% year over year, while AngioVac remained softer on a tougher comp but improved sequentially.
- Gross margin expanded to 59.4% from 55.3% a year ago, helped by pricing, mix shift, and tariff refunds.
- Management kept FY27 guidance intact: sales of $336 million to $341 million, gross margin of 54% to 55%, adjusted EBITDA of $13 million to $16 million, and adjusted loss per share of $0.29 to $0.24.
Q1 FY27 revenue increased 6.9% to $80.9 million. MedTech revenue was $39.9 million, up 13.2%, and Med Device revenue was $41 million, up 1.4%. Gross margin was 59.4%, up 410 basis points year over year; excluding tariff refunds, margin would have been 57.8%. GAAP net loss improved to $7.1 million, or $0.17 per share, from $10.9 million, or $0.26 per share, a year ago. Adjusted net loss was $1.8 million, or $0.04 per share, versus $4.2 million, or $0.10 per share, and adjusted EBITDA was $5 million versus $2.2 million. Full-year FY27 guidance calls for net sales of $336 million to $341 million, MedTech sales growth of 12% to 15%, Med Device sales roughly flat, gross margin of 54% to 55%, adjusted EBITDA of $13 million to $16 million, and adjusted loss per share of $0.29 to $0.24. Management said it remains on track to generate positive operating cash flow for the full fiscal year.
Jim Clemmer emphasized that the quarter validated AngioDynamics’ long-running transformation strategy, with growth coming from medtech platforms and a mix shift toward higher-margin products. He highlighted Auryon, mechanical thrombectomy, and NanoKnife as key catalysts, and stressed reimbursement progress and clinical studies as important for future expansion. His tone was confident and reflective, while also focused on the leadership transition to Eric Honer and continuity of execution.
Steve Trowbridge walked through a quarter with stronger revenue, margin, and earnings metrics, noting gross margin of 59.4% benefited from pricing, medtech mix, and $1.2 million of tariff refunds; absent that benefit, margin would have been 57.8%. He said operating cash flow was negative by $15.3 million in Q1, ending with $34 million in cash and a debt-free balance sheet, but reiterated the company expects positive operating cash flow for the full year. He also framed FY27 guidance around $336 million to $341 million of sales, 54% to 55% gross margin, and $13 million to $16 million of adjusted EBITDA, while saying tariff impact should be broadly similar to FY26.
Analysts pressed on NanoKnife utilization after system placement, asking when capital sales would translate into higher disposable growth. Management said disposables are the better way to view the business, with utilization varying by site and reimbursement progress, and pointed to strong procedure-volume trends and the CPT1 and Palmetto MAC wins. Questions on mechanical thrombectomy focused on new accounts and commercial changes; management said salesforce additions are now contributing, AlphaVac should drive growth, and AlphaReturn enrollment is progressing well. On cash usage, management said Q1 is typically the biggest cash outflow quarter because of compensation and tariffs, and that the usual seasonal cadence should continue.
The call showed multiple growth engines moving at once: Auryon kept its long streak of double-digit growth, AlphaVac accelerated, and NanoKnife saw strong prostate demand with record procedure volumes. Management sounded increasingly confident that medtech will become the majority of revenue this fiscal year, supported by better margins and a debt-free balance sheet.
AngioVac still declined year over year, and management acknowledged it is facing a tougher comp even though sequential trends improved. NanoKnife still depends on broader reimbursement adoption and site-level utilization ramps, and management said coverage is not yet fully consistent nationwide. Cash usage was a negative $15.3 million in the quarter, and tariff and manufacturing-transition effects remain a source of variability.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.9%
- Shares Outstanding
- 42.05M
- Float Shares
- 32.76M
of shares held by institutions
164 13F filers
Buy/sell ratio 1.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ANGO, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.05M | ▲ 245.70K |
| Point72 Asset Management, L.P. | 3.06M | ▼ 119.31K |
| Systematic Financial Management LP | 2.64M | ▲ 186.51K |
| Vanguard Group Inc | 2.44M | ▲ 72.69K |
| Armistice Capital, LLC | 2.20M | ▲ 329.00K |
| Royce & Associates LP | 1.92M | ▼ 48.31K |
| Broadfin Holdings LLC | 1.82M | ▼ 250.80K |
| Kotler Kevin | 1.71M | ▲ 1.71M |
| Vanguard Capital Management LLC | 1.71M | ▲ 17.36K |
| Weber Capital Management LLC /Adv | 1.35M | ▼ 6.70K |
| Arrowstreet Capital, Limited Partnership | 1.03M | ▲ 338.60K |
| Geode Capital Management, LLC | 1.01M | ▼ 5.96K |
Held by 174 ETFs
Biggest fund positions in ANGO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Honroth Eric | other | 38,265 |
| Nov 2, 26 | Honroth Eric | other | 62,928 |
| Nov 2, 26 | Honroth Eric | other | 62,928 |
| Nov 2, 26 | Honroth Eric | other | 0 |
| Oct 28, 26 | Trowbridge Stephen A | sell | 1,720 |
| Oct 29, 26 | Trowbridge Stephen A | sell | 23,615 |
| Jul 30, 26 | Nighan Warren JR | sell | 23,370 |
| Jul 22, 26 | Piccinini Laura | other | 8,047 |
| Jul 22, 26 | Piccinini Laura | other | 4,506 |
| Jul 22, 26 | Piccinini Laura | other | 28,336 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANGO coverage
Recent articles, reports, and earnings notes.
No research on ANGO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANGO report →Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
zacks.com · Nov 13
AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 6
AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE
businesswire.com · Oct 21
AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist
seekingalpha.com · Oct 15
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
gurufocus.com · Oct 14
AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer
businesswire.com · Oct 14
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
zacks.com · Oct 9
AngioDynamics Stock Is Falling Thursday: What's Going On?
benzinga.com · Oct 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.